Tvardi Therapeutics, Inc.

TVRDSEC EDGAR

Pharmaceutical Preparations(DE)CIK: 1346830

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue from Contract with Customer, Excluding Assessed Tax	$41.9M	$23.0M	$135.1M	$19.9M	$13.5M
Cost of Goods and Services Sold	—	—	—	$0.00	—
Research and Development Expense	$91.9M	$82.7M	$107.9M	$113.8M	$75.5M
Operating Expenses	$129.4M	$112.1M	$129.7M	$131.6M	$90.9M
Operating Income (Loss)	-$87.5M	-$89.1M	$5.4M	-$111.7M	-$77.4M
Other Nonoperating Income (Expense)	$2.1M	$642.0K	$2.3M	$4.5M	$3.0M
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	-$85.5M	—

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Assets	$125.8M	$182.2M	$247.1M	$271.2M	$233.0M
Assets, Current	$116.2M	$168.9M	$173.3M	$195.1M	$165.7M
Cash and Cash Equivalents, at Carrying Value	$51.8M	$63.7M	$13.5M	$31.7M	$18.3M
Accounts Receivable, after Allowance for Credit Loss, Current	$2.8M	$3.3M	—	—	—
Inventory, Net	$2.8M	$2.4M	$2.6M	$2.6M	—
Liabilities	$68.8M	$23.5M	—	—	—
Liabilities, Current	$25.6M	$23.5M	$17.6M	$18.5M	$42.9M

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Net Cash Provided by (Used in) Operating Activities	-$78.7M	-$60.1M	-$5.5M	-$109.2M	-$22.3M
Net Cash Provided by (Used in) Investing Activities	$128.7M	-$4.8M	-$20.3M	-$30.5M	-$82.8M
Net Cash Provided by (Used in) Financing Activities	$311.0K	$46.6M	$39.1M	$142.6M	$110.8M
Payments to Acquire Property, Plant, and Equipment	$43.0K	$39.0K	$349.0K	$18.0K	$73.0K

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)